Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
<h4>Background</h4>There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC).<h4>Methods</h4>The clinical charts of 233 patients with...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0258160 |